{"database": "press", "table": "releases", "rows": [["https://houlahan.house.gov/news/documentsingle.aspx?DocumentID=4837", "Houlahan and House Colleagues Introduce the Biomanufacturing Excellence Act", "2025-11-18", "2025", "2025-11", "Democrat", "House", "PA", "Chrissy Houlahan", "H001085", "houlahan.house.gov", "houlahan", "https://houlahan.house.gov/press/documentquery.aspx", "page_html", "Today, U.S. Representative Chrissy Houlahan and House colleagues Jim Baird (R-Ind.), David Rouzer (R-N.C.), and Deborah Ross (D-N.C.) introduced the Biomanufacturing Excellence Act, which would promote U.S. leadership in biotechnology and strengthen domestic biopharmaceutical manufacturing. Companion legislation is being led in the U.S. Senate by Senators Chris Coons (D-Del.) and Ted Budd (R-N.C.)\n\nBiotechnology will shape how the United States defends itself, secures its food supply, and cures life-threatening diseases. The National Security Commission on Emerging Biotechnology (NSCEB) warned that without rapid and significant investment, the U.S. will fall behind its global competitors, specifically China. China\u2019s share of global pharmaceutical output has surged from about 5% in 2002 to nearly 25% in 2019. This legislation reinvests in domestic biopharmaceutical manufacturing, reducing dependence on unreliable foreign supply chains, expanding access to cutting-edge medicines, and supporting high-quality American jobs.\n\nThe Biomanufacturing Excellence Act would establish a public-private center dedicated to advancing biopharmaceutical manufacturing \u2013 a key recommendation from the National Security Commission on Emerging Biotechnology (NSCEB) report.\n\nSpecifically, the National Biopharmaceutical Manufacturing Center of Excellence would:\n\nUnite industry professionals with academic researchers to conduct collaborative research on new technology for scaling biopharmaceutical manufacturing.\n\nHost a facility that replicates industrial manufacturing conditions and complies with FDA Current Good Manufacturing Practice (CGMP) regulations, where innovators would develop and test new manufacturing processes.\n\nIdentify challenges and opportunities for scaling biopharmaceutical manufacturing, especially for products important to U.S. national security, public health, and economic security.\n\nTrain tomorrow\u2019s biopharmaceutical manufacturing workforce by partnering with educational, industry, and community leaders to bolster biotechnology talent.\n\n\"Southeastern Pennsylvania has a storied history as a global leader in the life sciences. Yet too many of our breakthroughs struggle to reach patients and markets because we lack the biomanufacturing capacity to scale and commercialize them. That gap threatens jobs, our regional competitiveness, and our access to medicines, applications, solutions and treatments Americans and our nation need. Our bipartisan Biomanufacturing Excellence Act tackles this head-on by creating a national Center of Excellence to drive innovation in biopharmaceutical manufacturing. The bill would cut costs, speed production, and grow our biotech workforce here in our Commonwealth. As competitors like the Chinese Communist Party race to dominate this space, we cannot afford to fall behind,\u201d said Representative Chrissy Houlahan.\n\n\u201cA strong domestic biopharmaceutical manufacturing industry is vital to developing innovative treatments to cure and manage diseases, improving public health, and securing our supply chains,\u201d said Congressman Baird. \u201cCommunist China has been closing the innovation gap with the U.S., creating an urgent need for strengthening our domestic biomanufacturing capabilities. I\u2019m proud to join Congresswoman Houlahan on this bipartisan legislation to reduce our reliance on an adversary for life-saving treatments, encourage innovation in biopharmaceutical manufacturing, and ensure our country continues to lead the world in finding groundbreaking cures.\u201d\n\n\u201cBiotechnology is rapidly reshaping national defense, health security, and our economy\u2019s resilience. As home to one of the strongest biotech and biomanufacturing ecosystems in the country, North Carolina has demonstrated how innovation can strengthen America\u2019s ability to develop and produce life-saving medicines,\u201d said Congressman Rouzer. \u201cThe Biomanufacturing Excellence Act reaffirms our commitment to expanding that capacity here at home. By supporting public-private collaboration and growing our domestic manufacturing base, this legislation ensures the United States can remain competitive, reduce reliance on foreign supply chains, and equip the next generation of biotechnology leaders to drive our nation forward.\u201d\n\n\u201cNorth Carolina is a national leader in biotechnology and innovation,\u201d said Congresswoman Deborah Ross. \u201cOur state is home to world-class researchers and companies, who are changing the future of medicine and stand ready to spearhead our country\u2019s leadership in biomanufacturing. Investing in innovation here at home will strengthen our supply chains, make our communities more secure, bolster our economy, and help save lives. I\u2019m proud to join a bipartisan group of colleagues in introducing this important legislation that will invest in the future of medicine.\u201d\n\n\u201cDelaware and innovation have always gone hand in hand,\u201d said Senator Coons. \u201cThe extraordinary biomedical research that happens in the First State has grown our economy, turned start-ups into industry leaders, and saved lives around the world. China is surging ahead in biotechnology, putting our national security, economy, and health at risk. This bipartisan bill will ensure the United States continues to lead the world in biotech manufacturing, protecting Americans\u2019 security and our health.\u201d\n\n\u201cNot only is biomanufacturing a key pillar of America's and North Carolina\u2019s innovation economy, it has the potential to transform major aspects of everyday life. We must foster this critical technology and continue to lead the world in enabling life-saving medical breakthroughs, fortifying our critical supply chains, and creating good-paying, high-skilled jobs. I am proud to partner with Senator Coons to help build on the public-private partnerships that have unlocked significant economic potential and unleashed next-generation technology,\u201d said Senator Budd.\n\nThe bill is endorsed by the National Security Commission on Emerging Biotechnology (NSCEB), the Delaware BioScience Association, the Biotechnology Innovation Organization, the Information Technology and Innovation Foundation (ITIF), NCLifeSci and NCBiotech, Life Sciences Pennsylvania, and the American Alliance for Biomanufacturing.\n\n\"I am grateful to our congressional partners for their strong commitment to the future of U.S. biotechnology leadership and their introduction of this important legislation,\u201d said NSCEB Vice Chair Michelle Rozo. \u201cIn our report, we found that advancing innovation in the biopharmaceutical sector is essential to catalyzing full-scale production for new medicines in the United States, and this center would bring together industry, academia, and government to do just that. Through our Biotech Across America roadshow, I\u2019ve had the opportunity to personally visit biotech hubs around the country to see the impact this type of cutting-edge biomanufacturing innovation can have on U.S. national, health, and economic security.\u201d\n\n\u201cThe United States must remain the global leader in biopharmaceuticals and advanced manufacturing to safeguard our nation\u2019s health, economic vitality and national security. The National Biopharmaceutical Manufacturing Center of Excellence will help drive this mission forward by aligning industry, academia and workforce partners to test new technologies under real manufacturing conditions and train skilled professionals for great careers \u2013 ultimately accelerating innovation, lowering costs and getting more life-changing therapies to patients faster,\u201d said Michael Fleming, President and CEO, Delaware BioScience Association.\n\n\u201cITIF supports the bipartisan Biomanufacturing Excellence Act, which would create a National Biopharmaceutical Manufacturing Center of Excellence that would convene industry, academic, and government stakeholders to ensure that America leads in the biomanufacturing revolution of the future. With experts estimating that 60 percent of the world\u2019s physical inputs could be made using biological processes going forward, biomanufacturing won\u2019t just transform the future of medicines, but also everything from energy, to food, to industrial manufacturing. The Biomanufacturing Excellence Act will help equip the United States with the technology, workforce, and knowhow to achieve leadership in this critical emerging field,\u201da statement from the Information Technology and Innovation Foundation (ITIF) reads.\n\n\u201cThe creation of a National Biopharmaceutical Manufacturing Center of Excellence is pivotal to advancing US leadership in bioprocess innovation, supply chain resiliency, and workforce competitiveness. We greatly appreciate Congressional leadership in recognizing the importance of biomanufacturing to national and economic security. For over four decades, North Carolina has created an integrated ecosystem focused on a steadfast commitment to life sciences manufacturing, establishing the state as a global leader with over $17 Billion of investment and 7,500 jobs announced since 2021. This success is built on a community of partners that work to seamlessly integrate world-class institutions of innovation with over 150 life sciences manufacturing companies, forming a uniquely dense hub for accelerating the translation of cutting-edge biomanufacturing innovations to scaled commercial outputs,\u201d a joint statement from NCLifeSci and NCBiotech reads.\n\n\u201cWe are living in an extraordinary era for biotechnology\u2014one where innovation, data-driven insights, and public-private partnerships are transforming what\u2019s possible for patients. Maintaining U.S. leadership in this sector is critical for our economic and national security. The Biotechnology Innovation Organization applauds Senators Chris Coons and Ted Budd, and Representatives Chrissy Houlahan, David Rouzer, Deborah Ross, and Jim Baird for introducing legislation that will help grow and expand the biotechnology sector to more communities across the country and better position the U.S. to develop and manufacture the next generation of medical advances,\u201d said the Biotechnology Innovation Organization.\n\n\"Pennsylvania's collaborative life sciences ecosystem has made our commonwealth a national leader in biopharmaceutical manufacturing for decades. We recognize the importance of the bipartisan and bicameral Biopharmaceutical Manufacturing Center of Excellence Act. This legislation will help incentivize and protect national security as well as ensure a steadfast supply chain in delivering treatments and therapeutics in Pennsylvania, across the Country, and around the world,\u201dsaid Christopher P. Molineaux, President and CEO of Life Sciences PA.\n\n\u201cThe Biomanufacturing Excellence Act is a decisive investment in America\u2019s health, security, and economic strength. The American Alliance for Biomanufacturing is proud to support this effort to bring cutting-edge biomanufacturing back home,\u201dsaid Brooke Coleman, Executive Director, American Alliance for Biomanufacturing.\n\n# # #\n\nThe full text of the bill is available here.", 1, "2026-04-08T14:14:11Z", "2026-04-08T14:23:06Z"]], "columns": ["url", "title", "date", "year", "month", "party", "chamber", "state", "member_name", "bioguide_id", "domain", "scraper", "source", "date_source", "text", "has_text", "collected_at", "updated_at"], "primary_keys": ["url"], "primary_key_values": ["https://houlahan.house.gov/news/documentsingle.aspx?DocumentID=4837"], "units": {}, "query_ms": 0.7300758734345436, "source": "dwillis/congress-press", "source_url": "https://github.com/dwillis/congress-press", "license": "MIT", "license_url": "https://github.com/dwillis/congress-press/blob/main/LICENSE"}